Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


28.11.2022

1 BMJ
1 Clin Infect Dis
1 J Gen Virol
3 J Immunol
4 J Infect
8 J Infect Dis
1 J Virol
2 JAMA
4 Lancet
1 MMWR Morb Mortal Wkly Rep
1 N Engl J Med
1 PLoS Med
4 PLoS One
2 Science
25 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMJ

  1. MAHASE E
    Monkeypox: Single dose of smallpox vaccine offers 78% protection, UKHSA reports.
    BMJ. 2022;379:o2829.
    PubMed        


    Clin Infect Dis

  2. TADESSE BT, Bravo L, Marks F, Aziz AB, et al
    Impact of vaccination with SCB-2019 COVID-19 vaccine on transmission of SARS-CoV-2 infection: a household contact study in the Philippines.
    Clin Infect Dis. 2022 Nov 26:ciac914. doi: 10.1093.
    PubMed         Abstract available


    J Gen Virol

  3. DEMPSEY R, Ritter L, Parker L
    Strain development of A/H1N1pdm09 candidate vaccine viruses for the 2021-22 northern hemisphere influenza season.
    J Gen Virol. 2022;103.
    PubMed         Abstract available


    J Immunol

  4. MISE-OMATA S, Ikeda M, Takeshita M, Uwamino Y, et al
    Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant.
    J Immunol. 2022;209:2104-2113.
    PubMed         Abstract available

  5. ZHENG MZM, Fritzlar S, Wang Z, Tan TK, et al
    Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.
    J Immunol. 2022;209:1832-1836.
    PubMed         Abstract available

  6. BREZNIK JA, Huynh A, Zhang A, Bilaver L, et al
    Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination.
    J Immunol. 2022;209:1892-1905.
    PubMed         Abstract available


    J Infect

  7. ZHAO Y, Zhao Y, Zhou Y, Zhang Z, et al
    Inactivated COVID-19 vaccination and maternal renal function during early pregnancy: a retrospective cohort study of 6397 Chinese pregnant women.
    J Infect. 2022 Nov 22:S0163-4453(22)00676-4. doi: 10.1016/j.jinf.2022.
    PubMed        

  8. YARCI-CARRION A, Esparcia-Pinedo L, Mateo-Jimenez G, Alfranca A, et al
    Effect of a SARS-CoV-2 booster vaccine dose on the immune response of adults with Down syndrome.
    J Infect. 2022 Nov 20:S0163-4453(22)00675-2. doi: 10.1016/j.jinf.2022.
    PubMed        

  9. WANG X, Sima L
    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
    J Infect. 2022 Nov 20:S0163-4453(22)00674-0. doi: 10.1016/j.jinf.2022.
    PubMed         Abstract available

  10. WANG G, Zhao K, Han J, Hu Z, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Recombinant Protein Vaccine, SCTV01C in Unvaccinated Adults: A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial.
    J Infect. 2022 Nov 17:S0163-4453(22)00649-1. doi: 10.1016/j.jinf.2022.
    PubMed        


    J Infect Dis

  11. JONGKEES MJ, Geers D, Hensley KS, Huisman W, et al
    Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination.
    J Infect Dis. 2022 Nov 19:jiac451. doi: 10.1093.
    PubMed         Abstract available

  12. LIND ML, Copin R, McCarthy S, Coppi A, et al
    Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
    J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
    PubMed         Abstract available

  13. ILCHMANN H, Samy N, Reichhardt D, Schmidt D, et al
    Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic(R) induce durable B cell memory responses comparable to replicating smallpox vaccines.
    J Infect Dis. 2022 Nov 21:jiac455. doi: 10.1093.
    PubMed         Abstract available

  14. TOMETTEN I, Landmann S, Kantauskaite M, Lamberti J, et al
    Factors associated with vaccine-induced T cell immune responses against SARS-CoV-2 in kidney transplant recipients.
    J Infect Dis. 2022 Nov 21:jiac449. doi: 10.1093.
    PubMed         Abstract available

  15. DESILVA MB, Mitchell PK, Klein NP, Dixon BE, et al
    Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.
    J Infect Dis. 2022 Nov 23:jiac458. doi: 10.1093.
    PubMed         Abstract available

  16. WANG X, Zein J, Ji X, Lin DY, et al
    Impact of Vaccination, Prior Infection and Therapy on Omicron Infection and Mortality.
    J Infect Dis. 2022 Nov 23:jiac460. doi: 10.1093.
    PubMed         Abstract available

  17. VANNIER E, Richer LM, Dinh DM, Brisson D, et al
    Deployment of a reservoir-targeted vaccine against Borreliella burgdorferi reduces the prevalence of Babesia microti coinfection in Ixodes scapularis ticks.
    J Infect Dis. 2022 Nov 23:jiac462. doi: 10.1093.
    PubMed         Abstract available

  18. MONTO AS, Lauring AS, Martin ET
    SARS-CoV-2 Vaccine Strain Selection: Guidance from Influenza.
    J Infect Dis. 2022 Nov 25:jiac454. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  19. STEPHENS LM, Ross KA, McLellan JS, Narasimhan B, et al
    Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.
    J Virol. 2022;96:e0150222.
    PubMed         Abstract available


    JAMA

  20. SLOMSKI A
    Intranasal COVID-19 Vaccine Disappointing in First-in-Human Trial.
    JAMA. 2022;328:2003.
    PubMed        

  21. KUEHN BM
    Targeted Flu Vaccination Campaigns Needed for Certain Racial and Ethnic Groups.
    JAMA. 2022;328:2005.
    PubMed        


    Lancet

  22. HUF SW, Woldmann L, Crespo RF, Grailey K, et al
    Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK.
    Lancet. 2022;400 Suppl 1:S41.
    PubMed         Abstract available

  23. BURNS R, Campos-Matos I, Harron K, Aldridge RW, et al
    COVID-19 vaccination uptake for half a million non-EU migrants and refugees in England: a linked retrospective population-based cohort study.
    Lancet. 2022;400 Suppl 1:S5.
    PubMed         Abstract available

  24. ISBA R, Brennan L, Davies N, Knight J, et al
    Measles, mumps, and rubella vaccination coverage in children younger than 5 years attending a paediatric emergency department in Manchester, UK: a cross-sectional observational study.
    Lancet. 2022;400 Suppl 1:S51.
    PubMed         Abstract available

  25. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  26. MINTA AA, Ferrari M, Antoni S, Portnoy A, et al
    Progress Toward Regional Measles Elimination - Worldwide, 2000-2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:1489-1495.
    PubMed         Abstract available


    N Engl J Med

  27. CHALKIAS S, Feng J, Chen X, Zhou H, et al
    Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination.
    N Engl J Med. 2022 Nov 23. doi: 10.1056/NEJMc2212772.
    PubMed        


    PLoS Med

  28. NIELSEN KF, Moustsen-Helms IR, Schelde AB, Gram MA, et al
    Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    PLoS Med. 2022;19:e1004037.
    PubMed         Abstract available


    PLoS One

  29. LAKNEH EA, Mersha EA, Asresie MB, Belay HG, et al
    Knowledge, attitude, and uptake of human papilloma virus vaccine and associated factors among female preparatory school students in Bahir Dar City, Amhara Region, Ethiopia.
    PLoS One. 2022;17:e0276465.
    PubMed         Abstract available

  30. SARRIGEORGIOU I, Moschandreou D, Dimitriadis A, Tsinti G, et al
    Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers.
    PLoS One. 2022;17:e0277827.
    PubMed         Abstract available

  31. GALDIKIENE L, Jaraite J, Kajackaite A
    Trust and vaccination intentions: Evidence from Lithuania during the COVID-19 pandemic.
    PLoS One. 2022;17:e0278060.
    PubMed         Abstract available

  32. LIMANI F, Smith C, Wachepa R, Chafuwa H, et al
    Estimating the economic burden of typhoid in children and adults in Blantyre, Malawi: A costing cohort study.
    PLoS One. 2022;17:e0277419.
    PubMed         Abstract available


    Science

  33. KELVIN AA, Falzarano D
    The influenza universe in an mRNA vaccine.
    Science. 2022;378:827-828.
    PubMed         Abstract available

  34. AREVALO CP, Bolton MJ, Le Sage V, Ye N, et al
    A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.
    Science. 2022;378:899-904.
    PubMed         Abstract available


    Vaccine

  35. MATHEWS KO, Norris JM, Phalen D, Malikides N, et al
    Factors associated with Q fever vaccination in Australian wildlife rehabilitators.
    Vaccine. 2022 Nov 21:S0264-410X(22)01364-0. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  36. TRAN QM, Soda J, Siraj A, Moore S, et al
    Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling.
    Vaccine. 2022 Nov 21:S0264-410X(22)01426-8. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  37. SEEGER JD, Amend KL, Turnbull BR, Zhou L, et al
    Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States.
    Vaccine. 2022 Nov 21:S0264-410X(22)01307-X. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  38. GILLES C, Rozenberg S, Buxant F, Manigart Y, et al
    HPV genotyping in biopsies of HSIL and invasive cervical cancers in women living with HIV: A cohort- and a nested -case control study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01288.
    PubMed         Abstract available

  39. ZHOU W, Tang B, Bai Y, Shao Y, et al
    The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Vaccine. 2022;40:7141-7150.
    PubMed         Abstract available

  40. FABIANI M, Mateo-Urdiales A, Sacco C, Rota MC, et al
    Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
    Vaccine. 2022 Nov 14:S0264-410X(22)01399-8. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  41. VANWORMER JJ, Alicea G, Weichelt BP, Berg RL, et al
    COVID-19 vaccine coverage disparities in rural and farm children.
    Vaccine. 2022 Nov 14:S0264-410X(22)01403-7. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  42. KALKOWSKA DA, Wassilak SGF, Pallansch MA, Burns CC, et al
    Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Vaccine. 2022 Nov 16:S0264-410X(22)01336-6. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  43. KIM J, Kim ED, Shin HS, Han SJ, et al
    Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops.
    Vaccine. 2022 Nov 16:S0264-410X(22)01192-6. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  44. MOLL K, Lufkin B, Fingar KR, Ke Zhou C, et al
    Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Vaccine. 2022 Nov 8:S0264-410X(22)01373-1. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  45. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey.
    Vaccine. 2022 Nov 7:S0264-410X(22)01371-8. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  46. FRANCO C, Herazo-Padilla N, Castaneda JA
    A queueing Network approach for capacity planning and patient Scheduling: A case study for the COVID-19 vaccination process in Colombia.
    Vaccine. 2022;40:7073-7086.
    PubMed         Abstract available

  47. HASSAN YAM, Daud Ali M, Al-Eid RR, Al-Ghuraya FA, et al
    A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
    Vaccine. 2022;40:7087-7096.
    PubMed         Abstract available

  48. KAUFMANN J, DeVoe JE, Angier H, Moreno L, et al
    Association of parent influenza vaccination and early childhood vaccinations using linked electronic health record data.
    Vaccine. 2022;40:7097-7107.
    PubMed         Abstract available

  49. MARCHETTI F, Lamiani G, Bona M, Amerighi C, et al
    Developing communication tools on rotavirus vaccination to support family paediatricians in Italy.
    Vaccine. 2022;40:7108-7114.
    PubMed         Abstract available

  50. CAETANO C, Morgado ML, Patricio P, Leite A, et al
    Measuring the impact of COVID-19 vaccination and immunity waning: A modelling study for Portugal.
    Vaccine. 2022;40:7115-7121.
    PubMed         Abstract available

  51. TSURANE K, Umehara N, Nakayama T, Okada K, et al
    Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society.
    Vaccine. 2022;40:7122-7129.
    PubMed         Abstract available

  52. ZIMMERMAN T, Shiroma K, Fleischmann KR, Xie B, et al
    Misinformation and COVID-19 vaccine hesitancy.
    Vaccine. 2022 Nov 14:S0264-410X(22)01402-5. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  53. AMPOFO AG, Mackenzie L, Boyes AW
    HPV vaccination: Intention to participate among female senior high school students in Ghana.
    Vaccine. 2022 Nov 18:S0264-410X(22)01383-4. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  54. NIQUEUX E, Flodrops M, Allee C, Lebras MO, et al
    Evaluation of three hemagglutinin-based vaccines for the experimental control of a panzootic clade 2.3.4.4b A(H5N8) high pathogenicity avian influenza virus in mule ducks.
    Vaccine. 2022 Nov 18:S0264-410X(22)01398-6. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  55. NOVAK A, Hindriks E, Hoek A, Veraart C, et al
    Cellular and humoral immune responsiveness to inactivated Leptospira interrogans in dogs vaccinated with a tetravalent Leptospira vaccine.
    Vaccine. 2022 Nov 18:S0264-410X(22)01417-7. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  56. ZHANG Z, Shi J, Zhang X, Guo X, et al
    Willingness of parents of 9-to-18-year-old females in China to vaccinate their daughters with HPV vaccine.
    Vaccine. 2022 Nov 18:S0264-410X(22)01404-9. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  57. DE FIGUEIREDO A, Simas C, Larson HJ
    COVID-19 vaccine acceptance and its socio-demographic and emotional determinants: A multi-country cross-sectional study.
    Vaccine. 2022 Nov 10:S0264-410X(22)01310-X. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  58. UTAZI CE, Aheto JMK, Wigley A, Tejedor-Garavito N, et al
    Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria.
    Vaccine. 2022 Nov 19:S0264-410X(22)01420-7. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available

  59. FEKETE M, Horvath A, Santa B, Tomisa G, et al
    COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary.
    Vaccine. 2022 Nov 18:S0264-410X(22)01415-3. doi: 10.1016/j.vaccine.2022.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: